US 12,569,551 B2Granted

Modified immunogenic proteins

AssigneesInternational AIDS Vaccine Initiative, The Scripps Research Institute

InventorsWilliam Schief, Manyuan Ma, Jon Steichen, Xiaozhen Hu, Sebastian Raemisch, Alessia Liguori, Torben Schiffner, Jordan Willis, Christopher Cottrell

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

The invention relates to germline-targeting designs, stabilization designs, and/or combinations thereof, of proteins designed with modified surfaces helpful for immunization regimens, other protein modifications and/or development of nanoparticles, methods of making and using the same, and to (a) germline-targeting priming or boosting/shepherding immunogens to initiate or guide maturation of VRC01-class responses (b) PCT64/PG9-germline-targeting designs (c) BG18-germline-targeting designs or boosting/shepherding immunogens to initiate or guide maturation of BG18-like responses, and/or (d) trimer stabilization and presentation in a membrane-bound format.

A non-naturally occurring protein comprising an amino acid sequence selected from SEQ ID NO:

2, SEQ ID NO:
3, SEQ ID NO:
4, SEQ ID NO:
5, SEQ ID NO:
6, SEQ ID NO:
7, SEQ ID NO:
8, SEQ ID NO:
9, SEQ ID NO:
10, SEQ ID NO:
11, SEQ ID NO:
12, SEQ ID NO:
13, SEQ ID NO:
14, SEQ ID NO:
15, SEQ ID NO:
16, SEQ ID NO:
17, SEQ ID NO:
18, SEQ ID NO:
19, SEQ ID NO:
20, SEQ ID NO:
21, SEQ ID NO:
22, SEQ ID NO:
23, SEQ ID NO:
24, SEQ ID NO:
25, SEQ ID NO:
26, SEQ ID NO:
27, SEQ ID NO:
28, SEQ ID NO:
29, SEQ ID NO:
30, SEQ ID NO:
31, SEQ ID NO:
32, SEQ ID NO:
33, SEQ ID NO:
34, SEQ ID NO:
35, SEQ ID NO:
36, SEQ ID NO:
37, SEQ ID NO:
38, SEQ ID NO:
39, SEQ ID NO:
40, SEQ ID NO:
41, SEQ ID NO:
42, SEQ ID NO:
43, SEQ ID NO:
44, SEQ ID NO:
45, SEQ ID NO:
46, SEQ ID NO:
47, SEQ ID NO:
48, SEQ ID NO:
49, SEQ ID NO:
50, SEQ ID NO:
51, SEQ ID NO:
52, SEQ ID NO:
53, SEQ ID NO:
54, SEQ ID NO:
55, SEQ ID NO:
56, SEQ ID NO:
57, SEQ ID NO:
58, SEQ ID NO:
59, SEQ ID NO:
60, SEQ ID NO:
61, SEQ ID NO:
62, SEQ ID NO:
63, SEQ ID NO:
64, SEQ ID NO:
65, SEQ ID NO:
66, SEQ ID NO:
67, SEQ ID NO:
68, SEQ ID NO:
69, SEQ ID NO:
70, SEQ ID NO:
71, SEQ ID NO:
72 SEQ ID NO:
73, SEQ ID NO:
74, SEQ ID NO:
75, SEQ ID NO:
76, SEQ ID NO:
77, SEQ ID NO:
78, SEQ ID NO:
79, SEQ ID NO:
80, SEQ ID NO:
81, SEQ ID NO:
82, SEQ ID NO:
83, SEQ ID NO:
84, SEQ ID NO:
85, SEQ ID NO:
86, SEQ ID NO:
87, SEQ ID NO:
88, SEQ ID NO:
89, SEQ ID NO:
90, SEQ ID NO:
91, SEQ ID NO:
92, SEQ ID NO:
93, SEQ ID NO:
94, SEQ ID NO:
95, SEQ ID NO:
96, SEQ ID NO:
97, SEQ ID NO:
98, SEQ ID NO:
99, SEQ ID NO:
100, SEQ ID NO:
101, SEQ ID NO:
102, SEQ ID NO:
103, SEQ ID NO:
104, SEQ ID NO:
105, SEQ ID NO:
106, SEQ ID NO:
107, SEQ ID NO:
108, SEQ ID NO:
109, SEQ ID NO:
110, SEQ ID NO:
111, SEQ ID NO:
112, SEQ ID NO:
113, SEQ ID NO:
114, SEQ ID NO:
115, SEQ ID NO:
116, SEQ ID NO:
117, SEQ ID NO:
118, SEQ ID NO:
119, SEQ ID NO:
120, SEQ ID NO:
121, SEQ ID NO:
122, SEQ ID NO:
123, SEQ ID NO:
124, SEQ ID NO:
125, SEQ ID NO:
126, SEQ ID NO:
127, SEQ ID NO:
128, SEQ ID NO:
129, SEQ ID NO:
130, SEQ ID NO:
131, SEQ ID NO:
132, SEQ ID NO:
133, SEQ ID NO:
134, SEQ ID NO:
135, SEQ ID NO:
136, SEQ ID NO:
137, SEQ ID NO:
138, SEQ ID NO:
139, SEQ ID NO:
140, SEQ ID NO:
141, SEQ ID NO:
142, SEQ ID NO:
143, SEQ ID NO:
144, SEQ ID NO:
145, SEQ ID NO:
146, SEQ ID NO:
147, SEQ ID NO:
148, SEQ ID NO:
149, SEQ ID NO:
150, SEQ ID NO:
151, SEQ ID NO:
152, SEQ ID NO:
153, SEQ ID NO:
154, SEQ ID NO:
155, SEQ ID NO:
156, SEQ ID NO:
157, and SEQ ID NO:
158.

154 more elements

Facts

Application

18/048,960Filed 24 Oct 2022 · continuation in part

Priority

30 Apr 2020

Published

US 2023/0190914 A122 Jun 2023

Granted

10 Mar 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification16 codes

A61K 39/21
Viral antigens: retroviridae, e.g. equine infectious anemia virus
A61P 31/18
For RNA viruses: for HIV
C07K 14/005
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof: from viruses
A61K 39/12
Medicinal preparations containing antigens or antibodies: viral antigens

Family

Application63/018,198Us provisional application · filed 30 Apr 2020

Application63/018,220Us provisional application · filed 30 Apr 2020

Application63/018,229Us provisional application · filed 30 Apr 2020

Application63/018,245Us provisional application · filed 30 Apr 2020

Application63/018,254Us provisional application · filed 30 Apr 2020

Application63/018,204Us provisional application · filed 30 Apr 2020

Application63/018,234Us provisional application · filed 30 Apr 2020

Application63/154,708Us provisional application · filed 27 Feb 2021

PCT/US2021/030092Parent of this continuation-in-part · filed 30 Apr 2021

US 2023/0190914 A1Pre-grant publication · published 22 Jun 2023

US 12,569,551 B2This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

Claims19